Effects of a New Antipsychotic Drug (YKP1447) on Impaired Prepulse Inhibition Induced by Apomorphine and Phencyclidine in Rats.
- Author:
Byung Soo YOON
1
;
Eun Hye PARK
;
Eui Ho PARK
;
Jeong Tae KWON
;
Sung Bin HONG
;
Seon Min DONG
;
Yun Hee KIM
;
Joon HEO
;
Mi Kyung JI
;
Yong Gil KIM
;
Byong Sung KWAK
;
June Seek CHOI
;
Hyun Taek KIM
Author Information
1. Department of Psychology, Korea Unviersity, Seoul, Korea. neurolab@korea.ac.kr
- Publication Type:Original Article
- Keywords:
Apomorphine;
Phencyclidine;
New antipsychotic drug (YKP1447);
Prepulse inhibition
- MeSH:
Acoustics;
Animals;
Antipsychotic Agents;
Apomorphine;
Humans;
Mental Disorders;
Noise;
Phencyclidine;
Rats;
Schizophrenia
- From:Korean Journal of Psychopharmacology
2008;19(1):38-45
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: Schizophrenia, a devastating mental disorder, displays a wide range of cognitive impairments including attentional impairment. Prepulse inhibition (PPI), in which a startle response to a loud acoustic noise is reduced by a preceding auditory stimulus of a lower intensity, is impaired in schizophrenic patients and rats injected with apomorphine (APO) or phencyclidine (PCP) mimicking attentional deficits in schizophrenics. Here we examined therapeutic efficacy of a newly developed atypical antipsychotic compound (YKP1447;YKP) on PPI impairment induced by various doses of APO and PCP. METHODS: This study was composed of 3 experiments. YKP (0.5-15 mg/kg) or vehicle (VEH) was administered 15 min before the injection of APO (0.5 mg/kg, Exp1) or PCP (2.0 mg/kg, Exp2:1.5 mg/kg, Exp3). They were then tested for PPI in which a mix of startle stimulus and prepulse was presented. RESULTS: APO or PCP treatment effectively impaired PPI in tested animals (VEH/APO or VEH/PCP). Impaired PPI in APO group was reversed in animals that were pretreated with YKP (5-10 mg/kg) (Exp1). However YKP treatment was not effective in PCP group (Exp2-3). CONCLUSION: High concentration of YKP pretreatment had antipsychotic effect on APO-induced impairment in attentional function suggesting that the compound could potentially be used to treat cognitive impairment due to increased dopaminergic receptorbinding.
